Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 2519 miles
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia,PA

VISITS: 2 visits a week for 3 weeks

PHASE: I

NCT ID: NCT03955640

Hyperthermia and Olaparib for Breast Cancer That Has Come Back in the Chest Wall

A Pilot Trial of Hyperthermia in Combination With Olaparib in Breast Cancer Patients With Chest Wall Recurrences Scientific Title

Purpose
To determine the best dose and effects (good and bad) of olaparib (Lynparza®) when it is used along with hyperthermia.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) breast cancer who do not have an inherited BRCA mutation and whose cancer has come back in the chest wall.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice a day, for 1 month</li> <li class="seamTextUnorderedListItem">Hyperthermia treatment, twice a week, for 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lynparza is a type of targeted therapy called a PARP inhibitor. </li> <li class="seamTextUnorderedListItem">It is approved to treat patients with an inherited BRCA mutation who have HER2-negative metastatic breast cancer that was previously treated with chemotherapy. </li> <li class="seamTextUnorderedListItem">Hyperthermia is a treatment that uses heat to kill or damage cancer cells. It is being studied in clinical trials.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03955640' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/fda-approves-olaparib-for-brca-breast-cancer' target='_blank'>OncLive: FDA Approves Olaparib for BRCA+ Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/hyperthermia.html' target='_blank'>Cancer.org: Hyperthermia to Treat Cancer</a> </li></ul>
See more